Application

19406921 · DOSAGE FORMS FOR TYK2 INHIBITORS

Filed 2025-12-02 · Granted · Patent 12751948 (2026-10-06) The official file ↗The patent and its PDF ↗ · Art unit 1625 · Examiner Phillip Matthew Rzeczycki Hard · CPC A61K 9/146 · Bristol-Myers Squibb Company · COVINGTON & BURLING, LLP

Office actions

first was Non-final rejection

RCEs

no appeal

To first action

2.3 mo

to disposition 10.1 mo

Statutes raised

112 DP

1 actions read

Unlock the prosecution timelineIncluded in Pro, from $29 a month. Cancel any time.